Jun Wang, Ph.D.
Founder and CEO of iCarbonX
Jun Wang is the Founder and CEO of iCarbonX. He is also Board Member of the BGI (previously known as the Beijing Genomics Institute). He co-founded BGI in the 1999, which is now widely recognized as one of world’s premier research facilities committed to excellence in genome sciences. Dr. Wang also holds a position as an Ole Rømer professor at the University of Copenhagen.
He has authored 400+ peer-reviewed original papers – of which 100+ are published in Cell, Nature (including Nature series), N Engl J Med., and Science (26 as cover story). He has been recognized with an award from His Royal Highness Prince Foundation, Nature’s 10 – the year in Science (2012); “Highly Cited Researchers (2013/2014/2015)” “The Hottest Scientific Researchers” (by Thomson Reuters), “Rebels, leaders, innovators for the next 25 years” (by CNBC), “Fortune’s 40 under 40” from Fortune Magazine (2013), Lundbeck Talent Price, Outstanding Science and Technology Achievement from the Chinese Academy of Sciences, Outstanding Technical Talent, ZhouGuangZhao Award, TanJiaZeng Life Science Innovation Award, Top 10 Scientific Achievements In China, Major Award from Shenzhen Municipal Government, and Prize for Important Innovation and Contribution from Chinese Academy of Sciences.
His research focuses on genomics and related bioinformatics analysis of complex diseases and agricultural crops, with the goal of developing applications using the genomic information.
Dr. Wang also managed to have three round fund-raising (about 1B$) at BGI, and acquired a US public company: Complete Genomics. Oct 27th 2015, Dr. Wang founded a new institute/company, iCarbonX, aiming to establish a health-related big Omics data platform, to develop artificial intelligence engine to interpret and mine the data as well as to enable every individual to better manage their health and defeat diseases.
Larry Gold, Ph.D.
Chairman and Founder of Somalogic, Founder of NeXstar and Synergen
Dr. Larry Gold is the Founder and Chairman of the board, and Past CEO of SomaLogic. Prior to SomaLogic, he also founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases. Before forming NeXagen, he also co-founded and served as co-director of research at Synergen, Inc., a biotechnology company later acquired by Amgen, Inc.
Since 1970, Dr. Gold has been a professor at the University of Colorado at Boulder. While at the university, he served as the chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992. Dr. Gold has received many citations including the CU Distinguished Lectureship Award, the National Institutes of Health Merit Award, the Career Development Award, and the Chiron Prize for Biotechnology.
Deepak Asudani, MD, MPH
Associate Clinical Professor of Medicine at University of California, San Diego
Dr. Asudani is an Associate Clinical Professor of Medicine at University of California, San Diego. He graduated with Bachelors in Medicine and Surgery from Rajasthan University, India and went on to complete Internal Medicine residency from New York Medical College, New York. With strong interest in public policy, global health and population health he completed Masters in Public Health from University of Massachusetts, Amherst. An alumni of Harvard Kennedy School of Government Executive education, he is also actively engaged in various leadership roles. He serves as the Medical Director for Hospital Medicine International Patients’ Program and is Chair, Outreach and Clinical Integration. He has been actively engaged with the Practice Management Committee and Public Policy Committee of the Society of Hospital Medicine. This has allowed him to work closely with national thought leaders in public policy development and advocacy. He has a strong interest in applied genomics with particular focus on pharmacogenomics. He believes that modern day genomic sequencing technology delivers a more focused understanding of an individual’s genetic configuration, and in this context – a better pixelated understanding of personalized diagnostics and therapeutics. He will be a regular contributor to the Journal of Precision Medicine’s Clinical Perspective section.
Mark Boguski, MD
Chief Medical Officer of Inspirata, Inc.
Dr. Mark Boguski is the Chief Medical Officer of Inspirata, Inc. and founded the Precision Medicine Network in 2014. He is member of the U.S. National Academy of Medicine and a Fellow of both the College of American Pathologists and the American College of Medical Informatics. Dr. Boguski has served on the faculties of the U.S. National Institutes of Health, the Johns Hopkins University School of Medicine and Harvard Medical School and as an executive in the biotechnology and pharmaceutical industries. He is a former Vice President and Global Head of Genome and Protein Sciences at Novartis and a graduate of the Medical Scientist Training Program at Washington University in St. Louis.
Founder and CEO of Alva10
Hannah Mamuszka is the Founder and CEO of Alva10, a company focused on driving up the value of diagnostics in healthcare. Ms Mamuszka founded Alva10 after having spent almost 20 years in the Cambridge, MA biotech community, with extensive experience in both drug and diagnostic development, validation, and commercialization. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda).
Diagnostics are the key to Precision Medicine, but they need to be valued in the healthcare market in order to be successful. For years, diagnostics have been stuck in a downward cycle of value, with poor reimbursement leading to lack of investment, and lack of investment leading to sub-optimal clinical validation, leading back to poor reimbursement. Alva10 is changing that, bringing diagnostics to the forefront of Precision Medicine by partnering with payers and diagnostics companies using a proprietary algorithm to determine economic impact of diagnostics and create a new value based healthcare model.
Alan Sachs, MD, Ph.D.
Chief Scientific Officer for Thermo Fisher Scientific
Dr. Sachs leads efforts to maximize growth through investments in R&D that position the company to help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. He served as the Chief Scientific Officer for Life Technologies and Life Sciences Solutions Group within Thermo Fisher between 2012 and 2015. Prior to this role, Dr. Sachs was the Vice President of Exploratory and Translational Sciences at Merck Research Laboratories. During his ten years at Merck, he built and directed the global RNA Therapeutics Department, led the Rosetta Inpharmatics group, and led the Department of Molecular Profiling. Before joining Merck, Dr. Sachs was an Associate Professor of Molecular and Cell Biology at the University of California at Berkeley, and a Whitehead Institute Fellow at the Whitehead Institute in Cambridge, MA. Dr. Sachs graduated from Cornell University with a B.A. in Biochemistry, and at Stanford Medical School received his Ph.D. with Roger Kornberg in Cell Biology, his M.D., and performed post-doctoral research with Ron Davis. Dr. Sachs is on the Board of Directors for Imago BioSciences and Advisory Board for Bakar Fellows at University of California, Berkeley.
Dr. Simon Kos, MBBS, BSc, MBA
Chief Medical Officer, Worldwide Health, Microsoft
Dr. Simon Kos joined Microsoft in 2010 to bring health domain expertise to the health team. He brings insight and experience from over 17 years working in the healthcare and Health IT industries. As the doctor on Microsoft’s Worldwide Health team, he is responsible for clinical strategy and industry engagement. He raises awareness of the Microsoft brand, technologies and partner community, and works to find clinical relevance for Microsoft products.
Prior to coming to Microsoft, Dr. Kos worked with global health IT companies Cerner and InterSystems as they implemented some of the largest e-Health initiatives in the Asia-Pacific region. His responsibilities included product design and localisation, clinical engagement, industry thought leadership and team management. Before his career in health IT Dr. Kos practiced as a doctor at NSWHealth, Australia for several years with a focus on critical care.
Dr. Kos has an MBBS and BSc(Med) from UNSW, and an MBA with a major in change management from AGSM. He is passionate about improving healthcare through technology.
Gary Siuzdak, Ph.D.
Professor & Senior Director, The Scripps Research Institute
Gary Siuzdak is Professor and Director of the Scripps Center for Metabolomics at The Scripps Research Institute. He is an affiliate scientist at the Lawrence Berkeley National Lab and has served as Vice President of the American Society for Mass Spectrometry. His research includes developing novel technologies for metabolomics, imaging and system biology. He has over 200 peer-reviewed publications and two books including the “The Expanding Role of Mass Spectrometry in Biotechnology”.
Biosciences Area Principal Deputy at Lawrence Berkeley National Laboratory
Mary Maxon is the Biosciences Area Principal Deputy at Lawrence Berkeley National Laboratory, where she is responsible for developing strategies for the use of biosciences to address national-scale challenges in energy and environment. She has extensive experience in both the public and private sectors, having served as the Assistant Director for Biological Research at the White House Office of Science and Technology Policy (OSTP) in the Executive Office of the President, where she developed the National Bioeconomy Blueprint, Director of the Marine Microbiology Program at the Gordon and Betty Moore Foundation, and in executive and management roles at Cytokinetics and Microbia, Inc. Maxon received her Ph.D. from the University of California, Berkeley and performed postdoctoral research in biochemistry and genetics at the University of California, San Francisco.
Hans Erik Henriksen
CEO of Healthcare DENMARK
Hans Erik Henriksen is CEO of Healthcare DENMARK. Healthcare DENMARK is a public private partnership organization, with a national mandate to promote Danish healthcare solutions and competencies abroad. The partnership is a framework for linking international partners with efficient Danish solutions and does not represent individual companies. He has a solid healthcare background from different executive positions during the latest 20 years. He was CEO of the innovative Danish healthcare-IT company Cetrea, which during 2008- 2012 was established as a leading provider of solutions to the Danish market and during
the same period accessed markets in other Nordic countries, Germany, Netherlands and USA.
Before joining Cetrea, he was responsible for IBM Healthcare and Life Sciences in the Northern and Eastern part of Europe (the countries U.K., Ireland, South Africa, Germany, Austria, Switzerland, the Nordic Countries and Central and Eastern Europe).
Since 2008 he has also been engaged as board member in a number of different healthcare and healthcare-IT companies. During 2012 he was a member of the Danish Governments Growth team for Healthcare and welfare solutions.
Dr. John Rudan
Professor and Head of Department of Surgery
Britton Smith Chair in Surgery
Dr. Rudan is a Professor and Head of the Department of Surgery at Queen’s University, Kingston Health Sciences Centre. His clinical interest spans across computer-assisted orthopaedic surgery, total joint surgery to oncology. As Director of Clinical Research at the Human Mobility Research Centre (HMRC) and Britton Smith Chair, Dr. Rudan has made significant contributions to patient health and mobility through innovative surgical procedures.
Dr. Rudan is a pioneer in computer-aided research, particularly in Orthopaedics. His effort to integrate this type of surgical platform in the operating theatre has generated over 240 peer-reviewed publications. He also has broad experience in other surgical applications in Neurosurgery, General Surgery and Cardiac Surgery. Currently, in collaboration with the Laboratory for Percutaneous Surgery at Queen’s University, he is leading research in novel navigation for the resection of breast, liver and other soft tissue tumours.
Dr. Rudan is a named inventor on 23 patent applications and 25 patents worldwide, many of which have been licensed to Fortune 500 companies.
Patient Advocate at Inspire2Live
As a Patient Advocate of Inspire2Live Peter connects patients, researchers and clinicians to further research, treatments and care; in the Netherlands as well as international. He organizes congresses, lobbies the matrix of public authorities, health care organizations, insurance companies and health research institutes. Peter also gives lectures and talks to help patients and society to fight cancer where possible and live with cancer with a good quality of life. He writes blogs, articles and books that contribute to these topics. Peter shows people their shining and radiant possibilities in every possible situation and lets them exploit their talents in favour of others. He’s creating Awareness and Hope where hope comes through vision.
Peter is the co-founder of Alpe d’HuZes, the foundation that is most famous for the annual cycling event on Mount Alpe d’Huez and that raised over 125 million euro for the fight against cancer. He works at the Central Bank of the Netherlands as a program manager and advisor for complex and politically difficult problems. His employer facilitates him in this job. Peter was honoured with a doctorate in October 2012 at the Free University in Amsterdam for connecting patients, researchers and clinicians all over the world to contribute to the quality of life of patients and their loved ones.
Dr. Thomas Wilckens
CEO InnVentis Ltd.
Thomas Wilckens is an MD and serial entrepreneur. His current focus is venture InnVentis Ltd (Israel) and the convergence of multi-omics technologies with real-world clinical data and machine learning to enable PRECISION MEDICINE, Thomas is also the founder of the LinkedIn group PRECISION MEDICINE Insight an Associate at deep innovation GmbH, a boutique consultancy headed by the fmr. Head Group R&D Vodafone. Before joining deep innovation, he founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University before heading off to basic research as a scholar of the Max-Planck Society and the Max-Kade Foundation, NY. He held several postdoc positions at leading academic institutions before becoming an entrepreneur. Aside from his work in Precision Medicine he developed a novel concept for value creation in research intensive industries; i.e. “Symbiotic Innovation”. With regard to this project Thomas is an associate at the GLORAD Research Center for Global R&D Management St. Gallen/Shanghai. Thomas is convinced that we will see a disruption of current diagnostics & therapeutic concepts and related business models. This paradigm shift will be induced by the advent of even greater communication and computing capabilities in concert with progress in omics and sensor technologies; i.e. Precision Medicine will ultimately be supported by algorithms for prevention, diagnostics and therapeutic decision making and become available anywhere 24/7.
Yves A. Lussier, MD, FACMI
Associate Vice President for Data Science, The University of Arizona Health Sciences, Director, Center for Biomedical Informatics and Biostatistics
Dr. Lussier is the Associate Vice President for Data Science and Chief Knowledge Officer for The University of Arizona Health Sciences. He also currently serves as the Director of the Center for Biomedical Informatics and Biostatistics, Associate Director for Cancer Informatics and Precision Health, and the Associate Director for Informatics of the BIO5 Institute at The University of Arizona. He is an internationally renowned physician-scientist and a pioneer of the field of translational bioinformatics. A practitioner of medicine for over seventeen years, he has been a member of the administrative board of four hospitals and published over 150 scientific papers and books chapters. He previously served as Director of three NIH-Funded bioinformatics cores at Columbia University and the University of Chicago. Dr. Lussier co-founded Purkinje, the first tablet-based electronic medical records anchored on the first commercial ontology, as well as developed and implemented Vigilens, the first ontology-anchored clinical event monitor that has been in operation at the New York Presbyterian Hospital of Columbia University since 2002. Leveraging bio-ontologies, he has pioneered and enabled clinical interpretation of personal transcriptomes dynamics between two samples, thus abrogating cohort-based statistics requirements
Dr. Lussier strongly believes that since every patient is a unique individual with a wide range of variability in genes, environment, and lifestyle, it is necessary to devise custom strategies when designing treatment methods. In his role as the Director of the Center for Biomedical Informatics and Biostatistics (CB2), he leads the initiative to build a data-driven learning health system, advance precision medicine analytics, and translate Big Data science and genomic discoveries to clinical care for The University of Arizona’s research and clinical communities. In addition to his role with CB2, his research group conducts hypothesis-driven translational research in biomedical informatics using clinical and genomic big data, knowledge technologies, and networks to better understand the pathology, progression, and treatment for diseases at the individual patient level. They are developing scalable computational data science technologies to efficiently and affordably heal humanity – one person at a time.
Lynn G. Dressler, Dr.P.H.
Director of Personalized Medicine, Fullerton Genetics Center and Mission SECU Cancer Center, Mission Health.
Dr. Dressler joined Mission Health, in February 2013, to develop and direct the Personalized Medicine and Pharmacogenomics Program. Formerly a faculty member in the Schools of Medicine and Pharmacy at the University of North Carolina at Chapel Hill, and a founding member of the UNC Institute for Pharmacogenomics and Individualized Therapy, Dressler’s 30 year career spans translational laboratory research in cancer, health policy research and the ethical ,legal, and social implications (ELSI) of genomic medicine. Dressler holds a Master’s in Experimental Pathology, a doctorate in Health Policy and completed a fellowship in ELSI research. At UNC, her laboratory conducted the research study that directly led to the FDA approval of the HER2 FISH assay (PathVYsion ™), one of the first pharmacogenomic tests in solid tumors. In North Carolina, nearly 10 years prior to GINA, (Genetic Information Non Discrimination Act, Federal Statute), Dressler worked with the North Carolina General Assembly to pass a law to prohibit discrimination by employers and health insurance providers on the basis of an individual’s genetic information. She has over 100 publications in related fields.
Working closely with NIH/NCI/NHGRI, Dressler has served in many leadership roles (External Advisor to The Cancer Genome Atlas Study (TCGA); NCI caHUB ethics working group, co- Chair Correlative Sciences Committee of the Cancer and Leukemia Group B). She currently serves as a member of the Clinical Pharmacogenomics Implementation Committee (CPIC); an affiliate member of the NIH Consortium IGNITE, and a guest member of the Institute of Medicine’s Roundtable on Translating Genomic Findings to Improve Population Health.
Dr. Paul R. Billings, M.D., Ph.D, FACP, FACMG
Chair, Biological Dynamics, Inc.
Dr. Paul R. Billings is a board-certified internist and clinical geneticist. He is a Principal in the consultancy, the Bethesda Group and is Chairman of both PlumCare, LLc and Biological Dynamics, Inc. Dr. Billings has held appointments at Harvard University, UCSF, Stanford University and UCB. He is a co-founder and CMO of Omicia, Inc.
Atul Butte, MD, PhD
Director of the Institute of Computational Health Sciences
Atul Butte, MD, PhD is the inaugural Director of the Institute of Computational Health Sciences (ichs.ucsf.edu) at the University of California, San Francisco, and a Distinguished Professor of Pediatrics. Dr. Butte is also the Executive Director for Clinical Informatics across the six University of California Medical Schools and Medical Centers. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children’s Hospital Boston, then received his PhD from Harvard Medical School and MIT. Dr. Butte has authored nearly 200 publications, with research repeatedly featured in Wired Magazine, the New York Times, and the Wall Street Journal. Dr. Butte was elected into the National Academy of Medicine in 2015, and in 2013, he was recognized by the White House as an Open Science Champion of Change for promoting science through publicly available data. Dr. Butte is also a founder of three investor-backed data-driven companies: Personalis, providing clinical interpretation of whole genome sequences, Carmenta (acquired by Progenity), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs through open molecular data. Dr. Butte is a principal investigator of three major programs: the California Initiative to Advance Precision Medicine; the California Precision Medicine Consortium, helping recruit tens of thousands of participants into President Obama’s Precision Medicine Initiative; and ImmPort, the clinical and molecular data repository for the National Institute of Allergy and Infectious Diseases.
James N. Czaban
Partner & Chairman of the FDA and Medical Products Regulatory Practice Group at DLA Piper LLP
James N. Czaban is a Partner and the Chairman of the FDA and Medical Products Regulatory Practice Group at the international law firm DLA Piper LLP, in Washington, D.C. In nearly 25 years of private practice, Jim has focused on counseling pharmaceutical, medical device and diagnostic, and other life sciences clients on a broad range of complex regulatory strategies and compliance matters, and regularly represents such clients in legal, public policy, and enforcement matters before the FDA, other administrative agencies, and in the federal courts. Jim has been deeply involved in the law and regulation of Precision Medicine since mapping of the human genome was completed more than 15 years ago. In 2001, Mr. Czaban published one of the first scholarly legal analyses of FDA’s potential approaches to regulating Precision Medicine, titled “Pharmacogenomics: The Uncertain Path to Deciphering the Regulatory Genome,” and more recently, published a comprehensive analysis of FDA’s efforts to tighten its control over the development and commercialization of Precision Medicine technologies, in the article “Promotion of Precision Medicine Under Imprecise Rules” (FDLI 2016). Mr. Czaban is a recipient of the Burton Award for Legal Excellence (2010) for his groundbreaking work involving FDA regulation of, and patent litigation involving, the emerging field of biosimilar products. He earned his undergraduate degree from the University of California, Berkeley (1988), and his law degree from the University of Virginia School of Law (1992).
Emanuel Petricoin III, PhD
University Professor, Co-Director Center for Applied Proteomics and Molecular Medicine, George Mason University
Dr. Emanuel F Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program and a Senior Investigator within the Center for Biologics Evaluation and Research at the FDA from 1993-2005. Dr. Petricoin received his PhD in Microbiology from the University of Maryland in 1990. The focus of the CAPMM is the invention and use of proteomics technologies for personalized therapy, molecular diagnostics and biomarker discovery. He is a co-founder of 4 life science companies, including 2 precision medicine companies: Theranostics Health, Inc. and Perthera, Inc. located in McClean VA, where is a co-founder and Chief Science Officer. He is a co-inventor on 40 filed and published patents, and has authored over 360 peer-reviewed publications and invited reviews. He has authored over 45 book chapters, is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention and on the editorial board of JCO Precision Oncology, Proteomics, Biomedical Microdevices, Proteomics-Clinical Applications, Proteomics-Protocols, Molecular, Carcinogenesis, Journal of Personalized Medicine and Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO). He has received numerous awards including the University Professorship at George Mason University, the NIH Director’s Award, FDA Distinguished Scientist Award, 2015 Innovator of the Year Award, GAP50 Top Virginia Entrepreneurs, Nifty 50 Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award and is s Kentucky Colonel. He is the faculty representative to the George Mason University Research Foundation.
Dr. George Poste
Professor of Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University
Dr. Poste is currently the Professor of Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University. This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision medicine.
He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences and Scientific Advisory Boards at the University of Michigan, Synthetic Genomics and Haplogen GmbH.
He is a Fellow of the U.K. Royal Society, the Royal College of Pathologists and U.K. Academy of Medicine, Member, Council for Foreign Relations, and Institute of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.
Lee S. Schwartzberg, M.D., F.A.C.P.
Executive Director and Chief Medical Officer, the West Cancer Center
Lee S. Schwartzberg, M.D., F.A.C.P. is the Executive Director and chief medical officer of the West Cancer Center. He is a Professor of Medicine and Chief, Division of Hematology/Oncology at The University of Tennessee Health Science Center. Dr. Schwartzberg is board certified in internal medicine, hematology, and medical oncology. He also serves as President /CMO for Vector Oncology, an oncology specific SMO/CRO. He was the founding editor-in-chief of the journal Community Oncology and serves as the editor-in-chief of the website Practice Update Oncology. He serves on the editorial board of the Journal of Supportive Oncology and the ASCO post and is a reviewer for many journals including the New England Journal of Medicine and the Journal of Clinical Oncology. He also serves on the board of directors for the National Comprehensive Cancer Network. Dr. Schwartzberg’s major research interests are new therapeutic approaches to breast cancer, targeted therapy and supportive care having published over 150 research papers. He maintains a private practice in medical oncology focusing on breast cancer.
Paul Langley, PhD
Adjunct Professor, College of Pharmacy, University of Minnesota, Director, Maimon Research LLC
Dr Langley is a health economist with over 30 years’ experience in consulting, academia and the pharmaceutical industry. The focus of Dr Langley’s academic and consulting activities is on the evidence base to support clinical and formulary decisions. Over the past 15 years Dr Langley has advised health care systems in the US, Australia and the European Union on the need for processes to be put in place to ensure that claims made for products and devices, both clinical and cost-effective, meet the standards of normal science for evaluation and replication. Dr Langley has published widely and at present is directing a program at the University of Minnesota on formulary evaluation with particular emphasis on personalized and precision medicine claims. The critical feature is the presence of an interactive evidence base that supports at risk target populations in the long-term.